Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia’s Behind-The-Counter Experience Shows Little Use For U.S.

This article was originally published in PharmAsia News

Executive Summary

Australia's experience is cited by a U.S. study as demonstrating little use in creating a new class of drugs falling between prescriptions and over-the-counter. That is the conclusion of the Government Accountability Office that studied the projects of Australia, Italy, the Netherlands and United Kingdom. The study determined the experience of those countries showed no need for another class. The class at issue is "behind-the-counter," which proponents have promoted for drugs covering chronic conditions such as asthma, cholesterol and diabetes. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel